ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma
نویسندگان
چکیده
منابع مشابه
Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?
This 12-month dose-titration study assessed the effectiveness of budesonide/formoterol for maintenance plus relief with a control group using salmeterol/fluticasone for maintenance plus salbutamol for relief. Adolescents and adults (n = 2,143; mean forced expiratory volume in one second (FEV1) 73% predicted; mean inhaled corticosteroid (ICS) 884 microg.day(-1)) were randomised to budesonide/for...
متن کاملBudesonide/formoterol maintenance and reliever therapy versus free-combination therapy for asthma: a real-life study.
BACKGROUND This non-interventional real-life study (NCT00884689) compared budesonide/formoterol (Symbicort®) maintenance and reliever therapy (SMART™) with a free combination of inhaled corticosteroid (ICS) + long-acting β2-agonist (LABA) (in separate inhalers) and as-needed short-acting β2-agonist (SABA) in adult asthma patients with an exacerbation in the past 24 months. METHODS Asthma pati...
متن کاملBudesonide/Formoterol Maintenance and Reliever Therapy versus Free-Combination Therapy for Asthma: A Real-Life Study
The Global Initiative for Asthma (GINA) guideline emphasises the combination of inhaled corticosteroids (ICSs) and long-acting β2-agonists (LABAs) as the first-choice treatment in patients with asthma who are not controlled with ICS alone (GINA treatment Step 3 and higher) [1]. These treatments can be administered via two separate inhalers or as a fixed-dose combination via a single inhaler; th...
متن کاملCost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy
Study sample Of the 4,399 patients initially identified, 3,335 were eligible and were included in the final study sample. There were 1,123 patients (43% men) in the fixed-dose SAL-FLU group, 1,105 patients (41% men) in the BUD-FORM group and 1,107 patients (43% men) in the SMART group. The mean age of the patients was 38 years (age range: 12 to 83) in the fixed-dose SAL-FLU group, 38 years (age...
متن کاملBudesonide/formoterol for maintenance and reliever therapy: new quality in asthma management
10.2217/14750708.5.4.495 © 2 Asthma is a chronic inflammatory disease of the airways with variable symptoms and airway obstruction. The strategy of asthma management aims to prevent and relieve acute attacks and achieve long-term control of symptoms. Symbicort® is a fixed combination of the corticosteroid budesonide and the long-acting β2-agonist formoterol – the first component treats inflamma...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Journal
سال: 2020
ISSN: 0903-1936,1399-3003
DOI: 10.1183/13993003.01407-2019